Experts call for more vaccine implementation testing


As developers introduce new vaccines against a host of diseases, more implementation testing is required to best inform rollout decisions.

That’s the position of four experts from the World Health Organization, who published an article in The Lancet calling for implementation studies to serve as a third facet of vaccine research in addition to safety and efficacy testing.

The process, they say, is needed because up to now, implementation assessments have occurred in high-income countries, but new vaccines against dengue, typhoid, Ebola virus and other infectious diseases should have local implementation pilot tests to determine how most effectively to introduce the vaccines. Additionally, for other vaccines, it is “no longer appropriate to shoehorn every new vaccine into the already crowded routine infant immunisation schedule,” as some can’t be given inside the current schedule, the authors said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The publication comes as GlaxoSmithKline’s first-of-a-kind malaria vaccine Mosquirix undergoes the pilot projects following its EMA approval last year.  According to the authors “this approach will allow data collection to address uncertainties from the efficacy trials, without which responsible, full policy advice cannot be made.” And though the tests come with “substantial upfront costs” they will ultimately pay off due to cost savings, the authors point out.

In the case of Mosquirix, GSK ($GSK) has agreed to donate pilot test doses, the article stated.

In a separate vaccine rollout underway, Sanofi ($SNY) has said it is working with local authorities using an algorithm to determine on a country by country basis how best to introduce its new dengue vaccine Dengvaxia.

- here’s the article

Related Article:
NIH-supported malaria vax posts 'encouraging' PhI results


Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.